1. Home
  2. EFC vs NTLA Comparison

EFC vs NTLA Comparison

Compare EFC & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EFC
  • NTLA
  • Stock Information
  • Founded
  • EFC 2007
  • NTLA 2014
  • Country
  • EFC United States
  • NTLA United States
  • Employees
  • EFC N/A
  • NTLA N/A
  • Industry
  • EFC Real Estate
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • EFC Finance
  • NTLA Health Care
  • Exchange
  • EFC Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • EFC 1.4B
  • NTLA 1.2B
  • IPO Year
  • EFC 2010
  • NTLA 2016
  • Fundamental
  • Price
  • EFC $13.21
  • NTLA $12.27
  • Analyst Decision
  • EFC Strong Buy
  • NTLA Buy
  • Analyst Count
  • EFC 7
  • NTLA 20
  • Target Price
  • EFC $14.46
  • NTLA $32.30
  • AVG Volume (30 Days)
  • EFC 1.4M
  • NTLA 4.1M
  • Earning Date
  • EFC 11-05-2025
  • NTLA 11-06-2025
  • Dividend Yield
  • EFC 11.80%
  • NTLA N/A
  • EPS Growth
  • EFC N/A
  • NTLA N/A
  • EPS
  • EFC 1.24
  • NTLA N/A
  • Revenue
  • EFC $312,485,000.00
  • NTLA $52,857,000.00
  • Revenue This Year
  • EFC N/A
  • NTLA $8.32
  • Revenue Next Year
  • EFC $15.82
  • NTLA N/A
  • P/E Ratio
  • EFC $10.68
  • NTLA N/A
  • Revenue Growth
  • EFC 10.76
  • NTLA 14.99
  • 52 Week Low
  • EFC $11.12
  • NTLA $5.90
  • 52 Week High
  • EFC $14.40
  • NTLA $23.76
  • Technical
  • Relative Strength Index (RSI)
  • EFC 38.23
  • NTLA 61.09
  • Support Level
  • EFC $13.40
  • NTLA $10.89
  • Resistance Level
  • EFC $13.94
  • NTLA $12.03
  • Average True Range (ATR)
  • EFC 0.18
  • NTLA 0.69
  • MACD
  • EFC -0.08
  • NTLA 0.05
  • Stochastic Oscillator
  • EFC 2.67
  • NTLA 84.45

About EFC Ellington Financial Inc.

Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. it acquires reverse mortgage loans both through its origination activities and through secondary market purchases.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: